AMA & Researchers Launch New Vaccine Safety Review System
- The American Medical Association (AMA) and the Vaccine Integrity Project are launching a collaborative effort to independently review the safety and effectiveness of vaccines for the upcoming fall...
- For decades, the CDC’s Advisory Committee on Immunization Practices (ACIP) served as the primary body responsible for evaluating vaccine data and making recommendations for vaccine use in the...
- According to a joint statement released by the AMA and the Vaccine Integrity Project, the CDC’s vaccine review process has “effectively collapsed.” The groups also noted that several...
The American Medical Association (AMA) and the Vaccine Integrity Project are launching a collaborative effort to independently review the safety and effectiveness of vaccines for the upcoming respiratory virus season. This initiative comes amid concerns about changes to the vaccine review process at the Centers for Disease Control and Prevention (CDC), and aims to provide clinicians and the public with evidence-based information to inform vaccination decisions.
A Shift in Vaccine Policy Review
For decades, the CDC’s Advisory Committee on Immunization Practices (ACIP) served as the primary body responsible for evaluating vaccine data and making recommendations for vaccine use in the United States. This system, while not legally binding, was widely respected and followed by healthcare professionals, schools, and insurance providers. However, recent changes, including the removal of all 17 members of ACIP and their replacement with a new panel that includes individuals skeptical of vaccines, have raised alarms within the medical community.
According to a joint statement released by the AMA and the Vaccine Integrity Project, the CDC’s vaccine review process has “effectively collapsed.” The groups also noted that several medical organizations have been blocked from participating in the analysis of vaccines for the committee. These developments prompted the AMA and the Vaccine Integrity Project to establish an independent review system to ensure a continued, evidence-based approach to vaccine evaluation.
Focus on Flu, COVID-19, and RSV
The initial focus of this collaborative effort will be on vaccines for influenza, COVID-19, and respiratory syncytial virus (RSV) – three respiratory viruses that pose significant public health risks, particularly during the fall and winter months. These viruses collectively hospitalize and kill tens of thousands of Americans each year, underscoring the importance of informed vaccination strategies.
“Respiratory viruses hospitalize and kill tens of thousands of Americans every year, and vaccine decisions must be guided by facts, not politics or ideology,” said Michael Osterholm, PhD, MPH, Director of CIDRAP, the University of Minnesota’s Center for Infectious Disease Research and Policy, which houses the Vaccine Integrity Project. This statement highlights the core principle driving the new review process: a commitment to scientific rigor and objectivity.
Building on Previous Work and a Deliberative Approach
This new initiative builds upon a thorough evidence review completed for the respiratory virus season. The goal is to establish a structured and durable process for evaluating the science underpinning respiratory virus immunization. The AMA and the Vaccine Integrity Project plan to convene leading medical professional societies and public health organizations to define a comprehensive set of policy questions. This collaborative approach aims to ensure a broad range of perspectives are considered and that the review addresses the most pressing concerns.
The project intends to emulate the deliberative, evidence-driven approach traditionally used by the federal government. The emphasis is on producing data necessary to understand the risks and benefits of vaccine policy decisions for all populations. However, it’s important to note that the AMA and the Vaccine Integrity Project are not aiming to issue vaccine recommendations themselves. Instead, they intend to provide trusted, science-based reviews that can be used by doctors, state health officials, and others when making vaccination decisions.
Restoring Confidence in Vaccine Science
The launch of this independent review system reflects a broader effort to restore confidence in vaccine science and public health recommendations. The changes at the CDC have created uncertainty and raised questions about the objectivity of the vaccine review process. By establishing an independent, transparent, and evidence-based system, the AMA and the Vaccine Integrity Project hope to reassure clinicians and patients that vaccine decisions are being made based on the best available science.
As stated in the AMA press release, the goal is to “restore peace of mind for clinicians and patients by ensuring that experts are continuously evaluating vaccine safety and effectiveness using transparent, evidence-based methods.” This initiative represents a significant step towards ensuring that vaccine policy remains grounded in scientific evidence and serves the best interests of public health.
The recent decision to end the long-standing recommendation that all newborns receive the hepatitis B vaccine, made by the newly constituted ACIP, further underscores the need for independent scrutiny of vaccine recommendations. This decision, strongly opposed by many public health experts, highlights the potential consequences of a shift away from evidence-based decision-making.
The AMA and Vaccine Integrity Project’s review will be crucial in providing a reliable source of information as the respiratory virus season approaches, allowing healthcare providers and individuals to make informed choices about vaccination.